These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 5211352

  • 1. The physiologic availability of solid dosage forms of phenylbutazone. II. Correlation of in vivo physiologic availability and in vitro dissolution parameters.
    Withey RJ, Feng H, Cook D, Van Petten GR, Lettau HF.
    J Clin Pharmacol New Drugs; 1971; 11(3):187-96. PubMed ID: 5211352
    [No Abstract] [Full Text] [Related]

  • 2. The physiologic availability of solid dosage forms of phenylbutazone. I. In vivo physiologic availability and pharmacologic considerations.
    Van Petten GR, Feng H, Withey RJ, Lettau HF.
    J Clin Pharmacol New Drugs; 1971; 11(3):177-86. PubMed ID: 5211351
    [No Abstract] [Full Text] [Related]

  • 3. [Biological availability and solubility of phenylbutazone].
    Krówczyński L, Jachowicz R, Wajdowicz A.
    Folia Med Cracov; 1979; 21(1):141-7. PubMed ID: 396188
    [No Abstract] [Full Text] [Related]

  • 4. Biopharmaceutical assessment of phenylbutazone and indomethacin preparations.
    Turakka H, Airaksinen MM.
    Ann Clin Res; 1974; 6(0):suppl 11:34-43. PubMed ID: 4855463
    [No Abstract] [Full Text] [Related]

  • 5. Evaluation of dosage forms. IV. Studies on commercial phenylbutazone tablet dosage forms.
    Razdan B, Paradkar AR.
    Drug Dev Ind Pharm; 1998 Jul; 24(7):599-604. PubMed ID: 9876503
    [Abstract] [Full Text] [Related]

  • 6. The objective and timing of drug disposition studies, appendix IV. Phenylbutazone formulations: in vitro dissolution and in vivo performance.
    Leeson LJ, Shinal EC, Lukas G, Zak SB, Weiner M.
    Drug Metab Rev; 1975 Jul; 4(2):277-84. PubMed ID: 1222684
    [Abstract] [Full Text] [Related]

  • 7. The varying dissolution rates of phenylbutazone tablets.
    Thomas WH, McCarthy WB.
    N Z Med J; 1970 Oct; 72(461):250-3. PubMed ID: 5275017
    [No Abstract] [Full Text] [Related]

  • 8. The physiologic availability of phenylbutazone tablets marketed in India.
    Manek SP, Tipnis HP, Kulkarni RD.
    Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):163-7. PubMed ID: 7263103
    [Abstract] [Full Text] [Related]

  • 9. A level A in vitro/in vivo correlation in fasted and fed states using different methods: applied to solid immediate release oral dosage form.
    Souliman S, Blanquet S, Beyssac E, Cardot JM.
    Eur J Pharm Sci; 2006 Jan; 27(1):72-9. PubMed ID: 16169713
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Determination of physiologic availability of commercial phenylbutazone preparations.
    Chiou WL.
    J Clin Pharmacol New Drugs; 1972 Jul; 12(7):296-300. PubMed ID: 4483535
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The biopharmaceutical properties of solid dosage forms. I. An evaluation of 23 brands of phenylbutazone tablets.
    Searl RO, Pernarowski M.
    Can Med Assoc J; 1967 Jun 10; 96(23):1513-20. PubMed ID: 6026336
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation between the rate of dissolution and absorption of opipramol from solid oral forms.
    Kanarkowski R, Wichliński LM.
    Mater Med Pol; 1985 Jun 10; 17(2):85-7. PubMed ID: 4079473
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.